Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

British Journal of Clinical Pharmacology

Volumn 49, Issue SUPPL. 1, 2000, Pages 35-42

  Prakash, C ^a   Kamel, A ^a   Cui, D ^a   Whalen, R D ^a   Miceli, J J ^a   Tweedie, D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cytochrome P450; Drug interactions; Enzyme kinetics; Human liver microsomes; Ziprasidone

Indexed keywords

1 AMINOBENZOTRIAZOLE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; FURAFYLLINE; KETOCONAZOLE; PALIPERIDONE; QUINIDINE; RISPERIDONE; SULFAPHENAZOLE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ARTICLE; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METABOLISM; MASS SPECTROMETRY; MICROSOME; PRIORITY JOURNAL;

EID: 0034014925     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00151.x     Document Type: Article

References (30)

1. Kamel A, Prakash C. Identification of in vitro metabolites of CP-88,059 in humans: characterization of metabolites by LC-MS/MS. Proceedings of the 43rd ASMS Conference on Mass Spectrometry and Allied Topics 1995: 887.
2. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names and nomenclature. DNA Cell Biol 1993; 12: 1-51.
3. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1989; 40: 243-288.
4. Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies. JAMA 1993; 269: 1550-1552.
5. Tucker GT. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 1992; 30: 550-553.
6. Wrighton SA, Vandenbranden M, Stevens J, et al. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 1993; 25: 453-484.
7. Rodriguez AD. Use of in vitro metabolism studies in drug development. An industrial perspective. Biochem Pharmacol 1994; 48: 2147-2156.
8. 3H labelled ziprasidone. Drug Metab Dispos 1997; 25: 206-218.
9. Howard HR, Shenk KD, Smolarek TA, et al. Synthesis of 3H- and 14C-labeled CP-88,059: a potent atypical antipsychotic agent. J Labelled Compd Radiopharm 1994; 34: 117-125.
10. Tweedie DJ, Burke MD. Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism of the beta-carbolines harmine and harmol. Biochem Pharmacol 1983; 32: 653-663.
11. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
12. Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes, I. Evidence of its hemoprotein nature. J Biol Chem 1964; 239: 2370-2378.
13. Tassaneeyakul W, Birkett DJ, Veronese ME, et al. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993; 265: 401-407.
14. Miners JO, Smith KJ, Robson RA, et al. Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol 1988; 37: 137-144.
15. Meier UT, Kronbach T, Meyer UA. Assay of mephenytoin metabolism in human liver microsomes by high performance liquid chromatography. Anal Biochem 1985; 151: 286-291.
16. Kronbach T. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Meth Enzymol 1991; 206: 509-517.
17. Sonderfan AJ, Arlotto MP, Dutton DR, et al. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys 1987; 255: 27-41.
18. Orsi BA, Tipton KF. Kinetic analysis of progress curves. Meth Enzymol 1979; 63: 159-183.
19. Segel IH. In Enzyme Kinetics: Behaviours and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. New York: John Wiley and Sons. 1975; pp. 100-226.
20. Prakash C, Kamel A, Anderson W, Wilner K. Characterization of metabolites of ziprasidone in human by LC-MS/MS. Proceedings of the 44th ASMS Conference on Mass Spectrometry and Allied Topics 1995; 563.
21. Prakash C, Kamel A, Anderson W, Fouda H. Characterization of metabolites of CP-88,059 in rat using HPLC/RAM/-ESI/MS/MS. Proceedings of the 42nd ASMS Conference on Mass Spectrometry and Allied Topics 1994; 355.
22. Prakash C, Kamel A, Anderson W. Biotransformation of antipsychotic drug ziprasidone in dogs. Proceedings of the 4th International ISSX Meeting 312, 1995.
23. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
24. Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol 2000; 49(Suppl. 1): 57S-60S.
25. Testa B. In The Metabolism of Drugs and Other Xenobiotics. eds. Testa B, Caldwell J. New York, Academic Press. 1995; 203-234.
26. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257-268.
27. Heykants J. The pharmacokinetics of risperidone in humans. In The Ist International Risperidone Investigators Meeting; 1992; 19-20.
28. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of fluoxetine, norfluoxetine, sertraline and desmethylsertraline on human CYP3A catalyzed 1(-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995; 275: 131-135.
29. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44: 349-355.
30. Wilner KD, Demattos SB, Anziano RJ, Apseloff G, Gerber N. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolisers. Br J Clin Pharmacol 2000; 49(Suppl. 1): 43S-47S.